In case you missed it and are wondering where @isth.org #ISTH2027 will be held: 🇨🇦 VANCOUVER 🇨🇦! Under the leadership of ACPC Chair @marccarriermd.bsky.social Mark your calendars already for June 26-30, 2027. Read more at: bit.ly/4iJznfy
Marc Carrier, MD
@marccarriermd.bsky.social
Hematologist 🩸| Blood clot lover | Division Head @Ottawa Hospital | Senior Scientist @OHRI | Professor of Medicine at University of Ottawa
🩸 Key takeaways from 2025 CanVECTOR meeting Even with standard LMWH thromboprophylaxis, fewer than half of ICU patients reach target anti-Xa levels. 🔹 Sub-prophylactic anti-Xa levels → ~3× higher risk of VTE Time to reconsider “standard dosing” in the ICU.
Are you the person everyone calls when anticoagulation gets complicated? Then you’ll fit right in at the Thrombosis Canada Annual Conference! Join colleagues from across the country to connect, learn, and debate complex #VTE and #Anticoagulation cases during our Morning Report. thrombosiscanada.ca
Drs. Kevin Durr, Alexandre Tran & Marc Carrier's @marccarriermd.bsky.social study on personalized risk stratification and reduction of venous thromboembolism among critically ill patients: www.psifoundation.org/funded-resea... #WorldThrombosisDay #ThrombosisResearch @ottawahospital.on.ca
Funded Research - PSI Foundation
List of projects funded by PSI Foundation.
psifoundation.org
#AQUATICtrial In chronic coronary syndrome pts at high 🫀atherothrombotic risk on long-term oral anticoagulation (OAC), adding ASA ↑ CV events (HR 1.53), death (HR 1.72) & major bleeding (HR 3.35) without benefit. OAC alone safer. Published in @nejm.org www.nejm.org/doi/full/10....
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation | NEJM
The appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation remains unknown. We conducted a...
nejm.org
📢 New in @NEJM: In patients with provoked VTE + enduring risks, 12 mo of low-dose apixaban cut recurrent VTE by ~90% (1.3% vs 10.0%) 🩸 Major bleeding rare (1 pt). 👉 www.nejm.org/doi/full/10....
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | NEJM
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk f...
nejm.org
Radiotherapy may independently increase the risk of venous thromboembolism. 🩸⚡ This review in @rpth.bsky.social unpacks mechanisms, diagnostic challenges, and why thromboprophylaxis should be tailored rather than routine. 👉 doi.org/10.1016/j.rp... #Thrombosis #Oncology #CancerResearch
A new @thrombosiscan.bsky.social survey found that >50% of Canadian cancer patients have little or no awareness of cancer-associated thrombosis (CAT) — a major cause of death in cancer. 📊 Only 27% recalled being educated on CAT risks, yet most want more info! doi.org/10.1055/a-26...
☀️ A morning walk, fresh air, and great company – the perfect way to kick off a busy day at #ASHCRTI! 🏃♀️💬 Nothing like connecting with colleagues and faculty before diving into a full day of learning. Thanks to everyone who joined us this morning! 🙌 @ash.hematology.org
🧵1/ Diagnosing recurrent venous thromboembolism (VTE) is hard. The international, multicenter PREDICTORS study (n=723) shows that while clinical decision rules (CDRs) still help stratify risk, they’re less effective at ruling out recurrence without imaging. 🩺📉
🆕 A new study protocol START aims to investigate the best strategies to reduce risk of thrombosis and thrombocytopenia in cancer patients. @marccarriermd.bsky.social 👉 Click here to read more about the study design and goals! www.rpthjournal.org/article/S247...
Implementation matters! A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸 @marycushmanmd.bsky.social
🚨 SPECTACULAR RCT at #ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk— ✅ Supporting the safety of ruling out PE with a SPECT-based algorithm 📸 PE diagnosis rates matched other validated strategies SPECTacular findings indeed! 🫁💥
🩸 WaVE Study Alert! In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective. 🔹 Anti-Xa levels aligned with non-obese patients 🔹 Higher levels seen in those with bleeding Important data to guide dosing CAT & obesity. 📍Presented by Dr. Wang at #ISTH2025
📣 ARIVA Trial at #ISTH2025: 🧪 First RCT on antithrombotic therapy post-venous stenting for PTS 🔵 6-month primary patency rate was higher than expected 💊 No added benefit of aspirin + rivaroxaban vs. rivaroxaban alone www.ahajournals.org/doi/10.1161/...
📢 Long-term results from the CELEST trial presented at #ISTH2025: 🧦 No difference in burdensome PTS (~10%) between 25 vs. 35 mmHg ECS after proximal DVT. ✅ Compliance (>50% use) significantly lowers risk. 🔁 Findings reinforce 2-year RCT data. 📌 A placebo-controlled RCT is still needed.
Great provocative SOA by Dr. Eikeilboom: are there settings where warfarin outperforms DOACs in AF?💊 Emerging data suggest lower mortality & better overall clinical benefit in AF with obesity or rheumatic disease, possibly via GAS6 inhibition #ISTH2025 #AF #Thrombosis
🩸 Important findings from Dr @IMYanXu at #ISTH2025: Black individuals on extended anticoagulation for secondary VTE prevention had higher rates of major bleeding, including ICH, than White individuals. 🔎 No difference in CRNMB. 📢 Calls for action to address racial disparities.
🧠 #ISTH2025 SCC survey on stroke in cancer patients: 1️⃣ Physicians choose reperfusion strategies differently for patients with vs. without cancer 2️⃣ Antiplatelets remain the most used for secondary prevention 3️⃣ Major equipoise on workup post-stroke in cancer what is the standard of care?
Meta-analysis on GLP-1RA (vs. placebo) and VTE: 🔹 PE rates significantly lower 📉 🔹 VTE rates lower but not statistically significant 🔹 No difference in DVT 🔹 Study design matters: RCTs vs. observational data Accepted for publication in JTH! #ISTH2025 #VTE #GLP1RA #Thrombosis @jthjournal.bsky.social
Come say hello to David Airdrie, our Executive Director at Thrombosis Canada, at Booth 623! 👋 Learn more about our clinical guides, patient resources, and upcoming education initiatives. 📍 #ISTH2025 We’re here to connect! #ThrombosisCanada #VTE @thrombosiscan.bsky.social
📢 Adjust-DVT delivers practice-changing evidence! Age-adjusted D-dimer safely rules out DVT in patients with low or non-high pretest probability—reducing the need for ultrasounds. ✅ +17% yield in patients ≥75 years #ISTH2025 #DVT #Thrombosis #VTE
🩸 Clots strike twice—often in the same place. In a study of 708 patients with prior VTE, most recurrent events occurred at the same site as the original, especially in the same leg for prior DVT. #ISTH2025 #VTE #DVT #Thrombosis
📸 The Ottawa Thrombosis teams out celebrating wins and milestones at #ISTH2025! Proud of the science, the teamwork, and this amazing community. 🩸🥂
🩸 A new meta-analysis presented at #ISTH2025 and published in European Heart Journal identifies key risk factors (e.g., prior VTE or bleeding, advanced cancer, and certain cancer sites) linked to recurrent VTE and bleeding in patients with CAT 🔗 academic.oup.com/eurheartj/ad...
🩸 Curious if abiraterone interacts with DOACs in cancer patients? A large population-based study in men with prostate cancer found no increased bleeding risk with concurrent abiraterone + DOACs vs. other anticoagulants. 📍 #ISTH2025 📸 See findings below 👇
